All In Biotech

Drug Trial Radar · NCT04456673

Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate to Severe COPD With Type 2 Inflammation

A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety, and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) With Type 2 Inflammation

Last checked: Nov 20, 2026Latest source record: May 29, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Title says "pivotal". Randomized with 935 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

935

Actual

Start

Jul 6, 2020

Primary completion

Feb 28, 2024

Study completion May 27, 2024

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
Collaborators
Regeneron Pharmaceuticals
First posted
Jul 2, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 40 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Primary Objective: To evaluate the efficacy of dupilumab administered every 2 weeks in patients with moderate or severe Chronic Obstructive Pulmonary Disease (COPD) as measured by * Annualized rate of acute moderate or severe COPD exacerbation (AECOPD) Secondary Objectives: To evaluate the effect of dupilumab administered every 2 weeks on * Pre-bronchodilator forced expiratory volume in 1 second (FEV1) over 12 weeks compared to placebo * Health related quality of life, assessed by the change from baseline to Week 52 in the St. George's Respiratory Questionnaire (SGRQ) * Pre-bronchodilator FEV1 over 52 weeks compared to placebo * Lung function assessments * Moderate and severe COPD exacerbations * To evaluate safety and tolerability * To evaluate dupilumab systemic exposure and incidence of antidrug antibodies (ADA)

Conditions

  • Chronic Obstructive Pulmonary Disease

Interventions

  • Dupilumab SAR231893Drug

    Pharmaceutical form: Solution for injection Route of administration: Subcutaneous

  • Inhaled CorticosteroidDrug

    Pharmaceutical form: Inhaled Powder Route of administration: Oral inhalation

  • Inhaled Long-Acting Beta AgonistDrug

    Pharmaceutical form: Inhaled Powder Route of administration: Oral inhalation

  • Inhaled Long-Acting Muscarinic AntagonistDrug

    Pharmaceutical form: Inhaled Powder Route of administration: Oral inhalation

  • PlaceboDrug

    Pharmaceutical form: Solution for injection Route of administration: Subcutaneous

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Annualized Rate of Moderate or Severe Chronic Obstructive Pulmonary Disease (COPD) Exacerbations Over the 52-week Treatment PeriodTime frame: Baseline (Day 1) to Week 52

Locations

334 sites in 29 countries. Site status is shown where the registry gives one.

  • Cullman Research Center, LLC Site Number : 8400095

    Cullman, Alabama

  • Pulmonary & Sleep Associates of Jasper PC Site Number : 8400090

    Jasper, Alabama

  • Scottsboro Quick Care Clinic Site Number : 8400116

    Scottsboro, Alabama

  • Phoenix Medical Group Site Number : 8400061

    Peoria, Arizona

  • Medical Advancement Center of Arizona Site Number : 8400107

    Tempe, Arizona

  • Asthma and Allergy Institute Site Number : 8400022

    Little Rock, Arkansas

  • Kern Research, Inc Site Number : 8400031

    Bakersfield, California

  • NewportNativeMD, Inc Site Number : 8400032

    Newport Beach, California

  • Prospective Research Innovations, Inc. Site Number : 8400063

    Rancho Cucamonga, California

  • ACRC Studies Site Number : 8400094

    San Diego, California

  • Institute of HealthCare Assessment, Inc. Site Number : 8400015

    San Diego, California

  • Allianz Research Institute Site Number : 8400007

    Westminster, California

  • Innovative Clinical Research Site Number : 8400018

    Lafayette, Colorado

  • Helix Biomedics, LLC Site Number : 8400035

    Boynton Beach, Florida

  • Pioneer Clinical Research Site Number : 8400043

    Boynton Beach, Florida

  • Renaissance Research and Medical Group, Inc Site Number : 8400092

    Cape Coral, Florida

  • St. Francis Sleep, Allergy and Lung Institute Site Number : 8400020

    Clearwater, Florida

  • Beautiful Minds Clinical Research Center Site Number : 8400081

    Cutler Bay, Florida

  • Omega Research Consultants, LLC Site Number : 8400021

    DeBary, Florida

  • Sciences Connections, LLC Site Number : 8400133

    Doral, Florida

  • InvesClinic, LLC Site Number : 8400039

    Fort Lauderdale, Florida

  • Finlay Medical Research Site Number : 8400071

    Greenacres City, Florida

  • Direct Helpers Medical Center Inc Site Number : 8400079

    Hialeah, Florida

  • DL Research Solutions Inc Site Number : 8400089

    Miami, Florida

  • Phoenix Medical Research, LLC Site Number : 8400012

    Miami, Florida

  • Columbus Clinical Services Site Number : 8400062

    Miami, Florida

  • Reed Medical Research Site Number : 8400123

    Miami, Florida

  • De La Cruz Research Center, LLC Site Number : 8400075

    Miami, Florida

  • Florida Institute for Clinical Research Site Number : 8400129

    Orlando, Florida

  • Central Florida Pulmonary Group, PA Site Number : 8400101

    Orlando, Florida

  • Innovation Medical Research Center Site Number : 8400114

    Palmetto Bay, Florida

  • Family Medical Specialists of Florida, PA Site Number : 8400077

    Plant City, Florida

  • Coastal Pulmonary And Critical Care Site Number : 8400013

    St. Petersburg, Florida

  • Florida Pulmonary Research Center Site Number : 8400001

    Winter Park, Florida

  • Appalachian Clinical Research Site Number : 8400048

    Adairsville, Georgia

  • Northlake Medical Group Site Number : 8400099

    Atlanta, Georgia

  • River Birch Research, LLC Site Number : 8400045

    Blue Ridge, Georgia

  • Medical Centre of Conyers Site Number : 8400064

    Conyers, Georgia

  • David Kavtaradze MD, Inc. Site Number : 8400135

    Cordele, Georgia

  • Gwinnett Biomedical Research Site Number : 8400052

    Lawrenceville, Georgia

Showing 40 of 334 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.